CH622701A5 - - Google Patents

Download PDF

Info

Publication number: CH622701A5
Authority: CH; Switzerland
Prior art keywords: tetanus toxin; light chain; derivative; aldehyde; toxin
Prior art date: 1974-12-03

Application number

CH1548575A

Other languages

German (de)

English (en)

Inventor

Torsten Bertil Dr Helting

Original Assignee

Behringwerke Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-12-03

Filing date

1975-11-28

Publication date

1981-04-30

1975-11-28 Application filed by Behringwerke Ag filed Critical Behringwerke Ag

1976-05-26 Priority to AT388276A priority Critical patent/AT347448B/de

1977-06-07 Priority to AU25885/77A priority patent/AU510241B2/en

1981-04-30 Publication of CH622701A5 publication Critical patent/CH622701A5/de

Links

108010055044 Tetanus Toxin Proteins 0.000 claims description 34
229940118376 tetanus toxin Drugs 0.000 claims description 34
238000000034 method Methods 0.000 claims description 27
150000001299 aldehydes Chemical class 0.000 claims description 25
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 21
239000003795 chemical substances by application Substances 0.000 claims description 17
108090000623 proteins and genes Proteins 0.000 claims description 14
102000004169 proteins and genes Human genes 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 11
239000003053 toxin Substances 0.000 claims description 11
231100000765 toxin Toxicity 0.000 claims description 11
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
239000004202 carbamide Substances 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
125000001931 aliphatic group Chemical group 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims description 5
102000004142 Trypsin Human genes 0.000 claims description 5
108090000631 Trypsin Proteins 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 5
238000002955 isolation Methods 0.000 claims description 5
239000012588 trypsin Substances 0.000 claims description 5
101800002885 Tetanus toxin light chain Proteins 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 3
230000006334 disulfide bridging Effects 0.000 claims description 3
230000003834 intracellular effect Effects 0.000 claims description 3
235000018102 proteins Nutrition 0.000 description 13
239000000243 solution Substances 0.000 description 12
239000000047 product Substances 0.000 description 11
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
238000000926 separation method Methods 0.000 description 6
208000003217 Tetany Diseases 0.000 description 5
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
229960000789 guanidine hydrochloride Drugs 0.000 description 4
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
239000007858 starting material Substances 0.000 description 3
229960002766 tetanus vaccines Drugs 0.000 description 3
-1 thiol compounds Chemical class 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229960005367 tetanus antitoxin Drugs 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940031348 multivalent vaccine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

CH1548575A 1974-12-03 1975-11-28 CH622701A5 (fr)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
AT388276A AT347448B (de)	1975-11-28	1976-05-26	Verfahren zur herstellung von n-alkenyl-2- aminomethyl-pyrrolidinen
AU25885/77A AU510241B2 (en)	1975-11-28	1977-06-07	Producing tin or can covers

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2457047A DE2457047C3 (de)	1974-12-03	1974-12-03	Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe

Publications (1)

Publication Number	Publication Date
CH622701A5 true CH622701A5 (fr)	1981-04-30

Family

ID=5932347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH1548575A CH622701A5 (fr)	1974-12-03	1975-11-28

Country Status (17)

Country	Link
US (1)	US4029765A (fr)
JP (1)	JPS5182719A (fr)
AT (1)	AT342764B (fr)
AU (1)	AU504575B2 (fr)
BE (1)	BE836228A (fr)
CA (1)	CA1066621A (fr)
CH (1)	CH622701A5 (fr)
DE (1)	DE2457047C3 (fr)
DK (1)	DK544175A (fr)
ES (1)	ES443052A1 (fr)
FR (1)	FR2293217A1 (fr)
GB (1)	GB1531417A (fr)
IE (1)	IE42760B1 (fr)
IL (1)	IL48571A (fr)
LU (1)	LU73900A1 (fr)
NL (1)	NL7513941A (fr)
SE (1)	SE431401B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4200627A (en)	1976-07-31	1980-04-29	Behringwerke Aktiengesellschaft	Atoxic, immunogenic product of tetanus toxin
US4264588A (en) *	1979-05-10	1981-04-28	The Charles River Breeding Laboratories, Inc.	Vaccine for Clostridium perfringens type E enterotoxemia of rabbits
JPS5750925A (en) *	1980-09-12	1982-03-25	Takeda Chem Ind Ltd	Preparation of pertussis toxoid
US4594336A (en) *	1982-09-28	1986-06-10	Institut Pasteur	Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application
US5252714A (en) *	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
US6372225B1 (en)	1996-03-23	2002-04-16	The Research Foundation Of Microbial Diseases Of Osaka University	Tetanus toxin functional fragment antigen and tetanus vaccine
ES2237551T3 (es) *	2000-02-08	2005-08-01	Allergan, Inc.	Composiciones farmaceuticas que contienen toxina botulinica.
US7780967B2 (en) *	2000-02-08	2010-08-24	Allergan, Inc.	Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) *	2000-02-08	2006-11-30	Allergan, Inc.	Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030138460A1 (en) *	2000-02-08	2003-07-24	Allergan, Inc	Methods of treating animals with botulinum toxin pharmaceutical compositions
US8632785B2 (en) *	2000-02-08	2014-01-21	Allergan, Inc.	Clostridial toxin pharmaceutical composition containing a gelatin fragment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1617344B2 (de) *	1967-05-06	1976-04-08	Behringwerke Ag, 3550 Marburg	Verfahren zur herstellung eines tetanus-impfstoffes
US3903262A (en) *	1972-03-13	1975-09-02	Cutter Lab	Pharmaceutical compositions comprising intravenously injectable modified serum globulin, its production and use
DE2355094C3 (de) *	1973-11-03	1979-05-23	Behringwerke Ag, 3550 Marburg	Verfahren zur Herstellung eines Tetanus-Impfstoffs

1974
- 1974-12-03 DE DE2457047A patent/DE2457047C3/de not_active Expired
1975
- 1975-11-28 CH CH1548575A patent/CH622701A5/de not_active IP Right Cessation
- 1975-11-28 NL NL7513941A patent/NL7513941A/xx not_active Application Discontinuation
- 1975-11-28 ES ES443052A patent/ES443052A1/es not_active Expired
- 1975-11-30 IL IL48571A patent/IL48571A/xx unknown
- 1975-12-01 LU LU73900A patent/LU73900A1/xx unknown
- 1975-12-02 CA CA240,888A patent/CA1066621A/fr not_active Expired
- 1975-12-02 DK DK544175A patent/DK544175A/da not_active Application Discontinuation
- 1975-12-02 US US05/637,028 patent/US4029765A/en not_active Expired - Lifetime
- 1975-12-02 SE SE7513606A patent/SE431401B/xx unknown
- 1975-12-02 AT AT915575A patent/AT342764B/de not_active IP Right Cessation
- 1975-12-02 AU AU87167/75A patent/AU504575B2/en not_active Expired
- 1975-12-02 IE IE2621/75A patent/IE42760B1/en unknown
- 1975-12-03 BE BE162406A patent/BE836228A/fr not_active IP Right Cessation
- 1975-12-03 FR FR7536963A patent/FR2293217A1/fr active Granted
- 1975-12-03 GB GB49630/75A patent/GB1531417A/en not_active Expired
- 1975-12-03 JP JP50144567A patent/JPS5182719A/ja active Pending

Also Published As

Publication number	Publication date
FR2293217B1 (fr)	1978-07-28
US4029765A (en)	1977-06-14
DK544175A (da)	1976-06-04
SE7513606L (sv)	1976-06-04
LU73900A1 (fr)	1976-11-11
BE836228A (fr)	1976-06-03
ATA915575A (de)	1977-08-15
ES443052A1 (es)	1977-07-16
IE42760B1 (en)	1980-10-08
DE2457047B2 (de)	1979-03-15
DE2457047A1 (de)	1976-06-10
IE42760L (en)	1976-06-03
FR2293217A1 (fr)	1976-07-02
GB1531417A (en)	1978-11-08
IL48571A0 (en)	1976-01-30
NL7513941A (nl)	1976-06-08
AU504575B2 (en)	1979-10-18
JPS5182719A (en)	1976-07-20
DE2457047C3 (de)	1979-10-31
AU8716775A (en)	1977-06-09
AT342764B (de)	1978-04-25
CA1066621A (fr)	1979-11-20
IL48571A (en)	1980-02-29
SE431401B (sv)	1984-02-06

Legal Events

Date	Code	Title	Description
1986-07-31	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE68915045T2 (de)	1994-08-25	Reinigung von Pertussis-Toxinen und Herstellung von Vakzine.
Underdown et al.	1969	Isolation and characterization of an allergen from short ragweed pollen
DE2322552C2 (de)	1986-08-28	Verfahren zum Abtrennen von Protein A aus Staphylococcus aureus aus einer Flüssigkeit
DE2457047C3 (de)	1979-10-31	Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe
DE69124235T2 (de)	1997-05-28	Reinigung und verwendung von pertactin, eines bordetella pertussis aussenmembranproteins
DE60315827T2 (de)	2008-05-15	Verbesserte polysaccharid- und glykokonjugat-vakzine
DE3785157T2 (de)	1993-11-04	Verfahren zur herstellung von toxoid.
DE2355094C3 (de)	1979-05-23	Verfahren zur Herstellung eines Tetanus-Impfstoffs
CH628246A5 (de)	1982-02-26	Verfahren zur herstellung eines schuetzenden pertussis-antigens.
DE69731891T2 (de)	2005-12-01	Verfahren zur reinigung von gbs-toxin/cm101
DE2448530C3 (de)	1980-03-27	Verfahren zum Herstellen von Derivaten des Diphtherietoxins und diese enthaltende Mittel
DE69014541T2 (de)	1995-06-22	Chemisch modifizierte Allergene und Verfahren zu ihrer Herstellung.
DE69416983T2 (de)	1999-11-04	Zederpollen-Proteine und ihre Verwendung
DE3779914T2 (de)	1992-12-10	Neue lectine, abgeleitet von bakteriellen haaren.
DE2508396A1 (de)	1975-10-23	Verfahren zur gewinnung von virusproteinen, die dabei erhaltenen proteine und diese proteine als wirkstoffe enthaltende arzneimittel
WO1991004275A1 (fr)	1991-04-04	Nouvelles proteines servant a combattre des maladies et a proteger le betail contre les tiques
DE2404265A1 (de)	1975-07-31	Verfahren zur gewinnung von immunglobulinen
EP0083497A2 (fr)	1983-07-13	Procédé de préparation d'allergènes modifiés et leur usage pour le traitement d'états allergiques
DE2634584C3 (de)	1979-11-08	Atoxisches, immunogenes Produkt aus Tetanus-Toxin
Watanabe et al.	1979	Purification and some physicochemical properties of slow-reacting substance of anaphylaxis (SRS-A) from sensitized guinea pig lung
DE2815758C3 (de)	1982-02-18	Peptidkomplexe aus DNS-haltigen Organismen
DE2510987C2 (de)	1983-03-24	Verfahren zur Herstellung eines Tetanusimpfstoffes
DE2321951C2 (de)	1975-05-07	Verfahren zur Herstellung einer Diphtherie-Vaccine
AT234906B (de)	1964-07-27	Verfahren zur Herstellung eines neuen immunogenen Polysaccharids
CA1063021A (fr)	1979-09-25	Derives de la toxine tetanique, procede de preparation et agents les contenant